Meet our Life Sciences and Innovation team
Our UK network of offices is aligned to the Life Sciences and Innovation sector, operating across London, the Golden Triangle, and the UK Cities markets where innovation and research ecosystems thrive. Our team of sector experts can support your real estate requirements, both in the UK and globally within our Knight Frank platform.
Our team of advisors include:
|
|
Emma Goodford
Partner - Head of Life Sciences and Innovation - Occupational, Leasing and Development
Emma shares her knowledge of the Golden Triangle markets across a range of client projects. She is working with Brockton Everlast on the planned development of 10 acres in the heart of Cambridge Science Park. A recent fact finding trip to the US included tours of MIT/Kendall Square, Stanford Research Park and Berkeley, which are great places to see how ecosystems thrive, adjacencies create value and amenity, and service is king.
Also, in Cambridge she has been the consultant advising on the proposals, in public consultation, for the potential expansion of the Cambridge Biomedical Campus. In London, Emma is part of the Knight Frank team advising HIG and Lateral on a planned speculative lab development at Cavell Street, Whitechapel which will deliver almost 145,000 sq ft of bespoke lab enabled space in 2025/6.
|
Emma Goodford
Partner - Head of Life Sciences and Innovation - Occupational, Leasing and Development
Emma shares her knowledge of the Golden Triangle markets across a range of client projects. She is working with Brockton Everlast on the planned development of 10 acres in the heart of Cambridge Science Park. A recent fact finding trip to the US included tours of MIT/Kendall Square, Stanford Research Park and Berkeley, which are great places to see how ecosystems thrive, adjacencies create value and amenity, and service is king.
Also, in Cambridge she has been the consultant advising on the proposals, in public consultation, for the potential expansion of the Cambridge Biomedical Campus. In London, Emma is part of the Knight Frank team advising HIG and Lateral on a planned speculative lab development at Cavell Street, Whitechapel which will deliver almost 145,000 sq ft of bespoke lab enabled space in 2025/6.
|
|
|
Iain Keys
Partner, Office Head, Cambridge – UK Life Sciences and Innovation
Iain has been working in the life science sector for the last four years, focusing on development consultancy and investment. Based in Cambridge, Iain is embedded in the market and has a deep understanding of user requirements, provision of space and the ecosystem across the Arc. Iain has provided development consultancy advice on Howbery Park, near Oxford, a £200m opportunity to create the UK’s first cluster focused on water, climate change and the environment, chaired a government advisory panel to assist the government on shaping policy to develop the Cambridge Oxford Arc as well as investment advice and winning asset management instructions for life science space. He has extensive experience in advising on the creation of joint ventures, long term strategic advice, working with overseas investors and sustainability/green energy initiatives. Having worked as a consultant and client, he has a valuable understanding of client requirements and fund management. Over the last three years he has also worked on film studio development and is seen as a leading consultant in the sector. Clients include Biomed, IQHQ, TusPark, HR Wallingford.
|
Iain Keys
Partner, Office Head, Cambridge – UK Life Sciences and Innovation
Iain has been working in the life science sector for the last four years, focusing on development consultancy and investment. Based in Cambridge, Iain is embedded in the market and has a deep understanding of user requirements, provision of space and the ecosystem across the Arc. Iain has provided development consultancy advice on Howbery Park, near Oxford, a £200m opportunity to create the UK’s first cluster focused on water, climate change and the environment, chaired a government advisory panel to assist the government on shaping policy to develop the Cambridge Oxford Arc as well as investment advice and winning asset management instructions for life science space. He has extensive experience in advising on the creation of joint ventures, long term strategic advice, working with overseas investors and sustainability/green energy initiatives. Having worked as a consultant and client, he has a valuable understanding of client requirements and fund management. Over the last three years he has also worked on film studio development and is seen as a leading consultant in the sector. Clients include Biomed, IQHQ, TusPark, HR Wallingford.
|
|
|
Ben Anderson
Associate, Life Sciences & Innovation
Ben has 7+ years experience working in Life Sciences property development. Predominantly client-side. He worked for Bruntwood SciTech for 5 years, focused on Alderley Park (the former AstraZeneca site), ID Manchester, and regional projects in Birmingham, Liverpool, and Leeds. Ben then made the move to London to work for Guy’s and St Thomas’ Foundation on the Royal Street project (the 1.2m sq ft NIA MedTech scheme) in collaboration with Stanhope.
In August 2023, Ben joined Knight Frank as part of the growing Life Sciences team, advising on asset design, ecosystem building, and market dynamics and analysis. Ben possesses a deep knowledge of lab design and of mixed-use development and placemaking. And, importantly, a knowledge of why major cities across the globe are seeing the rise of ‘Innovation Districts’. Ben’s remit is nationwide, focusing on growing the UK offering as a whole.
|
Ben Anderson
Associate, Life Sciences & Innovation
Ben has 7+ years experience working in Life Sciences property development. Predominantly client-side. He worked for Bruntwood SciTech for 5 years, focused on Alderley Park (the former AstraZeneca site), ID Manchester, and regional projects in Birmingham, Liverpool, and Leeds. Ben then made the move to London to work for Guy’s and St Thomas’ Foundation on the Royal Street project (the 1.2m sq ft NIA MedTech scheme) in collaboration with Stanhope.
In August 2023, Ben joined Knight Frank as part of the growing Life Sciences team, advising on asset design, ecosystem building, and market dynamics and analysis. Ben possesses a deep knowledge of lab design and of mixed-use development and placemaking. And, importantly, a knowledge of why major cities across the globe are seeing the rise of ‘Innovation Districts’. Ben’s remit is nationwide, focusing on growing the UK offering as a whole.
|
|
|
Jennifer Townsend
Partner - Research Life Sciences
Jen is the author of the quarterly Life Sciences and Innovation Insight Report which tracks sector performance, events shaping the sector and leasing, development and investment activity. She also evaluates occupier demand across core life sciences clusters. This involves identifying emergent sub-sectors, proactively finding the most relevant occupiers for schemes and developing an in-depth understanding of occupiers through profiling.Jen is also responsible for thematic research focused on getting ahead of the macro and occupier trends shaping the sector and its real estate requirements.
Jen is also responsible for thematic research focused on getting ahead of the macro and occupier trends shaping the sector and its real estate requirements.
|
|
Jennifer Townsend
Partner - Research Life Sciences
Jen is the author of the quarterly Life Sciences and Innovation Insight Report which tracks sector performance, events shaping the sector and leasing, development and investment activity. She also evaluates occupier demand across core life sciences clusters. This involves identifying emergent sub-sectors, proactively finding the most relevant occupiers for schemes and developing an in-depth understanding of occupiers through profiling.Jen is also responsible for thematic research focused on getting ahead of the macro and occupier trends shaping the sector and its real estate requirements.
Jen is also responsible for thematic research focused on getting ahead of the macro and occupier trends shaping the sector and its real estate requirements.
|
|
|
Henry Wyld
Partner - Life Sciences and Capital Markets
Henry is working with Capital Markets clients across the Arc and advised L&G on the sale of 214-240 Cambridge Science Park. Henry works closely with clients including British Land, Runlabs, Angelo Gordon and Mission Street.
|
Henry Wyld
Partner - Life Sciences and Capital Markets
Henry is working with Capital Markets clients across the Arc and advised L&G on the sale of 214-240 Cambridge Science Park. Henry works closely with clients including British Land, Runlabs, Angelo Gordon and Mission Street.
|
|
|
Andrew Harrison
Partner - Life Sciences Capital Markets and Development
Andrew has over 15 years of experience providing clients with transactional and development consultancy advice across London. Advisory roles include underwriting and strategic buyside acquisition advice on the Department of Health Whitechapel Life Science Estate, Guys and St Thomas’ Snowsfields site, and the Royal Street Estate, Waterloo.
|
|
Andrew Harrison
Partner - Life Sciences Capital Markets and Development
Andrew has over 15 years of experience providing clients with transactional and development consultancy advice across London. Advisory roles include underwriting and strategic buyside acquisition advice on the Department of Health Whitechapel Life Science Estate, Guys and St Thomas’ Snowsfields site, and the Royal Street Estate, Waterloo.
|
|
|
Tom Coaker
Associate - Life Sciences and Capital Markets
Working closely with Mark Routledge, Tom advised Brookfield Asset Management on the purchase of the Atom Portfolio in 2021 which comprised 5 science and innovation parks for £714m, the largest transaction in the sector in the last 24 months.
Most recently he has worked with Cadillac Fairview and Stanhope Plc advising on the purchase of 194-198 Cambridge Science Park. Other assets Tom has advised on include Oxford Business Park and Cambridge Research Park. A selection of clients Tom has worked with include Brookfield Asset Management, RLAM, Cadillac Fairview and Stanhope Plc.
|
Tom Coaker
Associate - Life Sciences and Capital Markets
Working closely with Mark Routledge, Tom advised Brookfield Asset Management on the purchase of the Atom Portfolio in 2021 which comprised 5 science and innovation parks for £714m, the largest transaction in the sector in the last 24 months.
Most recently he has worked with Cadillac Fairview and Stanhope Plc advising on the purchase of 194-198 Cambridge Science Park. Other assets Tom has advised on include Oxford Business Park and Cambridge Research Park. A selection of clients Tom has worked with include Brookfield Asset Management, RLAM, Cadillac Fairview and Stanhope Plc.
|
|
|
Neil Mclocklin
Partner - Occupier Consultancy - Life Sciences and Innovation
Neil is responsible for Strategic Consulting within Knight Frank, working with businesses to align real estate to strategy. He has over 30 years of consultancy expertise, mainly focused on occupier portfolio, location and workplace strategies, across all sectors and with a strong focus on Life Sciences, where clients include Bayer, Cambridge Science Park – UK, Hydro-genics, London Watford Innovation and Incubation hub, Monheim Science Park - Germany, Novartis, Oxford - Harwell Science Campus, Plus X Innovation Hub - Brighton, RINA, Roche, Socotec, Shionogi, Takeda, Teva, UCB, AstraZeneca and GSK.
Over the last 10 years, he has been increasingly asked to turn his occupier lens around to help developers and investors re-position their assets or develop market strategies, particularly focus on tech and innovation. He has Master's degrees that span business strategy, technology, real estate and change management, at Universities that include UCL, Cass Business School and University of Southern California.
|
Neil Mclocklin
Partner - Occupier Consultancy - Life Sciences and Innovation
Neil is responsible for Strategic Consulting within Knight Frank, working with businesses to align real estate to strategy. He has over 30 years of consultancy expertise, mainly focused on occupier portfolio, location and workplace strategies, across all sectors and with a strong focus on Life Sciences, where clients include Bayer, Cambridge Science Park – UK, Hydro-genics, London Watford Innovation and Incubation hub, Monheim Science Park - Germany, Novartis, Oxford - Harwell Science Campus, Plus X Innovation Hub - Brighton, RINA, Roche, Socotec, Shionogi, Takeda, Teva, UCB, AstraZeneca and GSK.
Over the last 10 years, he has been increasingly asked to turn his occupier lens around to help developers and investors re-position their assets or develop market strategies, particularly focus on tech and innovation. He has Master's degrees that span business strategy, technology, real estate and change management, at Universities that include UCL, Cass Business School and University of Southern California.
|
|
|
Michael Crowe
Partner - Valuation and Advisory - Life Sciences
Michael has significant experience in valuing Life Science assets having valued over £4bn across the UK in the last 24 months including schemes in Oxford, Edinburgh, and the Golden Triangle.
|
Michael Crowe
Partner - Valuation and Advisory - Life Sciences
Michael has significant experience in valuing Life Science assets having valued over £4bn across the UK in the last 24 months including schemes in Oxford, Edinburgh, and the Golden Triangle.
|
|
|
Mark Routledge
Partner - Life Sciences and Capital Markets
Mark advised Brookfield Asset Management on the purchase of the Atom Portfolio in 2021, which comprised 5 science and innovation parks for £714m - the largest transaction in the sector in the last 24 months. Other assets Mark has advised on include Colworth Science Park, Granta Park, Chesterford Research Park, Oxford Business Park, Cambridge Science Park and Cambridge Research Park.
As well as living in Cambridge, Mark previously worked for MEPC and was involved in the inception and master planning of Granta Park still widely regarded as one of the best Life Science Park’s in the UK. Mark’s experience covers leasing, development, asset management, pre-purchase underwriting and strategic long-term advice and therefore is uniquely positioned to advise on the sector. A selection of clients Mark has worked with include Stanhope, Cadillac Fairview, Brookfield Asset Management, RLAM, Napp Pharmaceuticals, GSK, Blackstone, Aviva Investors and Columbia Threadneedle.
|
Mark Routledge
Partner - Life Sciences and Capital Markets
Mark advised Brookfield Asset Management on the purchase of the Atom Portfolio in 2021, which comprised 5 science and innovation parks for £714m - the largest transaction in the sector in the last 24 months. Other assets Mark has advised on include Colworth Science Park, Granta Park, Chesterford Research Park, Oxford Business Park, Cambridge Science Park and Cambridge Research Park.
As well as living in Cambridge, Mark previously worked for MEPC and was involved in the inception and master planning of Granta Park still widely regarded as one of the best Life Science Park’s in the UK. Mark’s experience covers leasing, development, asset management, pre-purchase underwriting and strategic long-term advice and therefore is uniquely positioned to advise on the sector. A selection of clients Mark has worked with include Stanhope, Cadillac Fairview, Brookfield Asset Management, RLAM, Napp Pharmaceuticals, GSK, Blackstone, Aviva Investors and Columbia Threadneedle.
|
Knight Frank Cresa Partnership
Across the US, Knight Frank and Cresa have come together to create something different, a streamlined service where client-focused outcomes are the only focus. The Knight Frank Cresa Life Sciences practice group operates in all key markets from Boston, to San Francisco and Seattle. Meet our Americas counterpart Matt Elmquist, Managing Principal, San Francisco, CA, Simon Terry Lloyd, Managing Principal, San Diego, CA, John Oakley, Principal, Boston, MA.